News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc. Hormone, Prempro Almost Double Breast Cancer Death Risk in U.S. Research
October 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Pfizer Inc.’s Prempro, a hormone once used by millions of women to ease menopause symptoms, almost doubled the death risk from breast cancer, a U.S. study found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Pfizer
MORE ON THIS TOPIC
Autoimmune disease
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data
October 28, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data
October 27, 2025
·
2 min read
·
Dan Samorodnitsky
Special edition
Deep Dive: Chinese Biotech Innovation Can’t Be Stopped
October 27, 2025
·
3 min read
·
Annalee Armstrong
Rare diseases
Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity
October 27, 2025
·
2 min read
·
Tristan Manalac